Navigation Links
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Date:8/30/2007

esting.

Phenoxodiol is being investigated as a therapy for late-stage, chemoresistant ovarian, prostate and cervical cancers. Phenoxodiol has received Fast Track status from the FDA to facilitate development as a therapy for recurrent ovarian and prostrate cancers.

Phenoxodiol is an investigational drug and, as such, is not commercially available. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by FDA as being safe and effective for the intended use.

About Marshall Edwards Inc:

Marshall Edwards, Inc. (Nasdaq: MSHL) is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from a flavonoid technology platform which has generated a number of novel compounds characterized by broad ranging efficacy against a range of cancer targets with few side effects. The unique combination of efficacy and safety has been explained by their ability to target an enzyme present on the surface of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards, Inc. has licensed rights from Novogen Limited (Nasdaq: NVGN) to bring three oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to market globally. Marshall Edwards, Inc. is majority owned by Novogen, an Australian biotechnology company that is specializing in the development of therapeutics based on a flavonoid technology platform. Novogen, based in Sydney, Austra
'/>"/>

SOURCE Marshall Edwards Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...NE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIFICA...EMENT IN DAILY FUNCTION, IN, ...if., and BRUSSELS, Belgium, Nov. 20 /PRNewswire-Fi... JAZZ ) and UCB (Euronext Brussels: UCB),announce... the first of two,Phase III pivotal clinical tria...
(Date:11/20/2008)... 20 Duska Therapeutics,... that it has submitted its,pivotal Phase 3 ATPace...l,Protocol Assessment (SPA) procedure with the U....ubject to securing an agreement with the FDA, Dusk...le-blind, placebo-controlled and randomized Phase ...
(Date:11/20/2008)...vember 20 The Scandinavian-based d...nced results of studies on its,lead antimicrobial...on, DC,the studies showed that the novel lytic p...fect, significantly better towards killing Staphyl...rketed gold standard drugs. In,addition to this i...
(Date:11/19/2008)...port basic findings on critical enzyme,s regulatio...t an array of disorders , , MEMPHIS, Tenn.,... St. Jude Children,s Research Hospital have gained... enzyme workhorses called calpains. , , As...tion in many cellular processes, including the mov...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3National Federation of the Blind to Award 24100 000 7690 1National Federation of the Blind to Award 24100 000 7690 2Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 7685 1Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 7685 2ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2082 1ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2082 2New choices for patients 3A Transfusion free medicine for Jehovahs Witnesses and transfusion wary 7681 1New choices for patients 3A Transfusion free medicine for Jehovahs Witnesses and transfusion wary 7681 2
...IRE)--Mar 27, 2007 - Interleukin,Genetics, Inc. (A...lifornia San Diego today reported at the American ...ions between coronary artery,disease (CAD) and bot...ppear to be dependent on pro-inflammatory variants...tion titled "The Influence of Oxidized,Phospholipi...
...l for Vaccine Delivery System, NYON, Switzerland, ...Corporation announced today that the Company,s HIV...human primate model.,Mucosal IgA antibodies are co...infection by HIV. The data were presented by,Sylva...er in an,oral presentation, "Without Mucosal Adjuv...
Other Medicine Technology:ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 2ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4
(Date:11/21/2008)... preterm labor , , FRIDAY, Nov. 21 (Heal...witch that activates the uterine muscles for contr...to therapies for preterm labor. , The molecule... surface of these uterine muscle cells, keeping th... researchers from Dartmouth Medical School in New ...
(Date:11/21/2008)...ate University College of Medicine research team l...w layer of regulation in the cell division cycle, ... way cancer begins. , Wang, an assistant profess...ne, said the findings will lead to an improved abi...gn of new drugs that kill cancer cells by inhibiti...
(Date:11/21/2008)...FirstCall/ -- Heska Corporation,(Nasdaq: HSKA )...ociety of,Security Analysts, 12th Annual Biotech ...08 at 1177 Avenue of the Americas, 2nd Floor in Ne...n at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain T...r two weeks,following the presentation through a ...
(Date:11/21/2008)... future antibiotic resistance from widespread use ...- People with moderate to severe chronic obstructi...the frequency of exacerbations through a regular, .... , The study, published in the first issue fo... and Critical Care Medicine , found that twice-dai...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2
...aimed to prevent more sudden deaths than defibrill... defibrillators according to US scientists.// Rese...mpared such preventive strategies by food suppleme... computer-simulated community of 100,000 people th...
...and why some people are hairier than others may ha...s.// The molecular mechanisms that determine whic...es, deciding the body's hair pattern has been disc...niversity of Manchester. This study on mice will ...
...wo-thirds of the people in the US do not wash thei...t had been newly formed had conducted the survey o... that the participants had been chosen from around..., United Arab Emirates, India, Malaysia, and South...
...n commissioned by the Australian government states... might be an cost effective option to control// th...rt also stated that to have found the various prog...ive, but raised questions about the effectiveness ...
Other Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia
Inquire
...'000 tests per year through automatic scheduling a... processing up to 4 assays on 4 plates simultaneou...to presentation of the results, are controlled by ... tube rack) and 256 (POS-ID Linear Rack) samples c...
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
Medicine Products: